Simon B. Lang
Research Subjects
Simon B. Lang has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Gary A. Molander
Département Médicaments et Technologies pour la Santé (DMTS) SCBM INRAE CEA Université Paris Saclay 91191 Gif‐sur‐Yvette France
8 shared publications - Christopher B. Kelly
Johnson & Johnson Innovative Medicine
6 shared publications - Jon A. Tunge
Department of Chemistry, The University of Kansas, 1567 Irving Rd., Lawrence, Kansas 66045, United States
5 shared publications - James P. Phelan
GSK Department of Medicinal Chemistry 1250 South Collegeville Road Collegeville PA 19426 United States
4 shared publications - Rebecca J. Wiles
Department of Chemistry University of Pennsylvania 231 S. 34th St. Philadelphia PA 19104
4 shared publications Esther Kofman
Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, California 94080, United States
3 shared publications
Latest Publications
- 30 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 9952-9976
Discovery of Novel N -Linked Camptothecin Linker-Payloads to Access Antibody–Drug Conjugates with High Target-Mediated In Vivo Efficacy
Antibody-drug conjugates (ADCs) are transforming oncology by enabling targeted delivery of potent cytotoxic agents to tumors. However, challenges such as resistance and limited response to established ADCs highlight the need for improved linkers and novel payloads driven by rational multivariate design and extensive synthetic optimization. We describe a discovery chemistry campaign for novel camptothecin-based linker-payloads enabling high drug-to-antibody ratio (DAR) ADCs with good biophysical properties, good in vitro potency, and strong in vivo efficacy. Starting from exatecan, amine-containing cytotoxic analogs were synthesized and evaluated for potency and permeability. Optimization of protease-cleavable p-aminobenzyl carbamate (PABC) linkers with a focus on stability and polarity leads to the discovery of promising α-amino-isobutyramido-exatecan constructs. The corresponding high-DAR ADCs showed low aggregation, good in vitro potency, and robust target-mediated efficacy in vivo across two antibody-antigen pairs. These results demonstrate the potential of these linker-payloads and the broad applicability of this design strategy.
- 30 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 9952-9976
Discovery of Novel N -Linked Camptothecin Linker-Payloads to Access Antibody–Drug Conjugates with High Target-Mediated In Vivo Efficacy
Antibody-drug conjugates (ADCs) are transforming oncology by enabling targeted delivery of potent cytotoxic agents to tumors. However, challenges such as resistance and limited response to established ADCs highlight the need for improved linkers and novel payloads driven by rational multivariate design and extensive synthetic optimization. We describe a discovery chemistry campaign for novel camptothecin-based linker-payloads enabling high drug-to-antibody ratio (DAR) ADCs with good biophysical properties, good in vitro potency, and strong in vivo efficacy. Starting from exatecan, amine-containing cytotoxic analogs were synthesized and evaluated for potency and permeability. Optimization of protease-cleavable p-aminobenzyl carbamate (PABC) linkers with a focus on stability and polarity leads to the discovery of promising α-amino-isobutyramido-exatecan constructs. The corresponding high-DAR ADCs showed low aggregation, good in vitro potency, and robust target-mediated efficacy in vivo across two antibody-antigen pairs. These results demonstrate the potential of these linker-payloads and the broad applicability of this design strategy.
- 30 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 9928-9951
Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug Conjugates
Through their uniquely effective combination of a target-selective antibody and a highly potent cytotoxic payload, antibody-drug conjugates (ADCs) are transforming cancer therapy. Nonetheless, the field has discovered that the multiparameter optimization of each component to further improve the balance of stability, efficacy, and tolerability is highly complex. However, synthetic and medicinal chemists are perfectly positioned to address such multifaceted design and accessibility challenges. The work described here outlines such an SAR campaign for the design and development of novel camptothecin-derived linker-payloads, with the most promising candidates leveraging a unique butanediol Exatecan-amide payload, an Ala-Ala protease-cleavable peptide linker, and a self-hydrolyzing maleimide with an α-branching PEGylated amide moiety, which provide low-aggregating (in vitro or in vivo) ADCs that demonstrate significant tumor regression in vivo. These linker-payloads are promising new leads for the treatment of cancer and represent a generalizable, modular, and advantageous linker platform.
- 30 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 9928-9951
Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug Conjugates
Through their uniquely effective combination of a target-selective antibody and a highly potent cytotoxic payload, antibody-drug conjugates (ADCs) are transforming cancer therapy. Nonetheless, the field has discovered that the multiparameter optimization of each component to further improve the balance of stability, efficacy, and tolerability is highly complex. However, synthetic and medicinal chemists are perfectly positioned to address such multifaceted design and accessibility challenges. The work described here outlines such an SAR campaign for the design and development of novel camptothecin-derived linker-payloads, with the most promising candidates leveraging a unique butanediol Exatecan-amide payload, an Ala-Ala protease-cleavable peptide linker, and a self-hydrolyzing maleimide with an α-branching PEGylated amide moiety, which provide low-aggregating (in vitro or in vivo) ADCs that demonstrate significant tumor regression in vivo. These linker-payloads are promising new leads for the treatment of cancer and represent a generalizable, modular, and advantageous linker platform.
- 22 August 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (17) , 15756-15779
Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody–Drug Conjugate Payloads
Toll-like receptors 7 and 8 are involved in modulating the adaptive and innate immune responses, and their activation has shown promise as a therapeutic strategy in the field of immuno-oncology. While systemic exposure to TLR7/8 agonists can result in poor tolerance, combination therapies and targeted delivery through antibody-drug conjugates (ADCs) can help mitigate adverse effects. Described herein is the identification of a novel and potent series of pyrazolopyrimidine-based TLR7/8 agonists with tunable receptor selectivity. Representative agonists from this series were successfully able to induce the production of various proinflammatory cytokines and chemokines from human peripheral blood mononuclear cells. Anti-HER2-25 and anti-HER2-26 ADCs made from this class of payloads demonstrated mechanism-based activation of TLR7/8 in a THP1/N87 coculture system.
- 22 August 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (17) , 15756-15779
Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody–Drug Conjugate Payloads
Toll-like receptors 7 and 8 are involved in modulating the adaptive and innate immune responses, and their activation has shown promise as a therapeutic strategy in the field of immuno-oncology. While systemic exposure to TLR7/8 agonists can result in poor tolerance, combination therapies and targeted delivery through antibody-drug conjugates (ADCs) can help mitigate adverse effects. Described herein is the identification of a novel and potent series of pyrazolopyrimidine-based TLR7/8 agonists with tunable receptor selectivity. Representative agonists from this series were successfully able to induce the production of various proinflammatory cytokines and chemokines from human peripheral blood mononuclear cells. Anti-HER2-25 and anti-HER2-26 ADCs made from this class of payloads demonstrated mechanism-based activation of TLR7/8 in a THP1/N87 coculture system.
- 11 November 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (47) , 25842-25849
Nickel-Catalyzed Antibody Bioconjugation
New biocompatible methods for post-translational protein modification are challenging to develop but crucial to create improved chemical probes and optimize next-generation biologic therapies such as antibody-drug conjugates (ADCs). Herein, we describe the bottom-up construction of an aqueous nickel-catalyzed cross-coupling for the chemospecific arylation of cysteine residues on peptides and proteins and its use for the preparation of ADCs. A variety of arene linkages are exemplified, enabling the incorporation of small molecules, probes, and cytotoxic payloads. The utility of this new bioconjugation platform in a drug discovery setting is highlighted by the construction of novel ADCs with target-mediated in vitro cytotoxic activity.
- 11 November 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (47) , 25842-25849
Nickel-Catalyzed Antibody Bioconjugation
New biocompatible methods for post-translational protein modification are challenging to develop but crucial to create improved chemical probes and optimize next-generation biologic therapies such as antibody-drug conjugates (ADCs). Herein, we describe the bottom-up construction of an aqueous nickel-catalyzed cross-coupling for the chemospecific arylation of cysteine residues on peptides and proteins and its use for the preparation of ADCs. A variety of arene linkages are exemplified, enabling the incorporation of small molecules, probes, and cytotoxic payloads. The utility of this new bioconjugation platform in a drug discovery setting is highlighted by the construction of novel ADCs with target-mediated in vitro cytotoxic activity.
- 8 May 2020
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 22 (11) , 4180-4184
A General One-Pot Protocol for Hindered N-Alkyl Azaheterocycles from Tertiary Carboxylic Acids
In this letter, we report a general one-pot strategy that utilizes three elementary steps (decarboxylative hydrazination, Boc deprotection, and heterocycle condensation) to regioselectively prepare hindered C(sp3) substituted pyrazoles and triazoles. The operational simplicity of this sequence and ubiquity of tertiary carboxylic acids allow rapid access to hindered N-alkyl azaheterocycles that will be useful to practitioners of medicinal chemistry and agro-chemistry.
- 8 May 2020
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 22 (11) , 4180-4184
A General One-Pot Protocol for Hindered N-Alkyl Azaheterocycles from Tertiary Carboxylic Acids
In this letter, we report a general one-pot strategy that utilizes three elementary steps (decarboxylative hydrazination, Boc deprotection, and heterocycle condensation) to regioselectively prepare hindered C(sp3) substituted pyrazoles and triazoles. The operational simplicity of this sequence and ubiquity of tertiary carboxylic acids allow rapid access to hindered N-alkyl azaheterocycles that will be useful to practitioners of medicinal chemistry and agro-chemistry.
- 12 February 2019
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 141 (8) , 3723-3732
Open-Air Alkylation Reactions in Photoredox-Catalyzed DNA-Encoded Library Synthesis
DNA-encoded library (DEL) technology is a powerful tool commonly used by the pharmaceutical industry for the identification of compounds with affinity to biomolecular targets. Success in this endeavor lies in sampling diverse chemical libraries. However, current DELs tend to be deficient in C(sp3) carbon counts. We report unique solutions to the challenge of increasing both the chemical diversity of these libraries and their C(sp3) carbon counts by merging Ni/photoredox dual catalytic C(sp2)–C(sp3) cross-coupling as well as photoredox-catalyzed radical/polar crossover alkylation protocols with DELs. The successful integration of multiple classes of radical sources enables the rapid incorporation of a diverse set of alkyl fragments.
- 12 February 2019
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 141 (8) , 3723-3732
Open-Air Alkylation Reactions in Photoredox-Catalyzed DNA-Encoded Library Synthesis
DNA-encoded library (DEL) technology is a powerful tool commonly used by the pharmaceutical industry for the identification of compounds with affinity to biomolecular targets. Success in this endeavor lies in sampling diverse chemical libraries. However, current DELs tend to be deficient in C(sp3) carbon counts. We report unique solutions to the challenge of increasing both the chemical diversity of these libraries and their C(sp3) carbon counts by merging Ni/photoredox dual catalytic C(sp2)–C(sp3) cross-coupling as well as photoredox-catalyzed radical/polar crossover alkylation protocols with DELs. The successful integration of multiple classes of radical sources enables the rapid incorporation of a diverse set of alkyl fragments.
- 19 June 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (25) , 8037-8047
Redox-Neutral Photocatalytic Cyclopropanation via Radical/Polar Crossover
A benchtop stable, bifunctional reagent for the redox-neutral cyclopropanation of olefins has been developed. Triethylammonium bis(catecholato)iodomethylsilicate can be readily prepared on multigram scale. Using this reagent in combination with an organic photocatalyst and visible light, cyclopropanation of an array of olefins, including trifluoromethyl- and pinacolatoboryl-substituted alkenes, can be accomplished in a matter of hours. The reaction is highly tolerant of traditionally reactive functional groups (carboxylic acids, basic heterocycles, alkyl halides, etc.) and permits the chemoselective cyclopropanation of polyolefinated compounds. Mechanistic interrogation revealed that the reaction proceeds via a rapid anionic 3-exo-tet ring closure, a pathway consistent with experimental and computational data.
- 19 June 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (25) , 8037-8047
Redox-Neutral Photocatalytic Cyclopropanation via Radical/Polar Crossover
A benchtop stable, bifunctional reagent for the redox-neutral cyclopropanation of olefins has been developed. Triethylammonium bis(catecholato)iodomethylsilicate can be readily prepared on multigram scale. Using this reagent in combination with an organic photocatalyst and visible light, cyclopropanation of an array of olefins, including trifluoromethyl- and pinacolatoboryl-substituted alkenes, can be accomplished in a matter of hours. The reaction is highly tolerant of traditionally reactive functional groups (carboxylic acids, basic heterocycles, alkyl halides, etc.) and permits the chemoselective cyclopropanation of polyolefinated compounds. Mechanistic interrogation revealed that the reaction proceeds via a rapid anionic 3-exo-tet ring closure, a pathway consistent with experimental and computational data.
- Open Access
- 25 May 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 9 (22) , 5119
Correction: Rapid access to diverse, trifluoromethyl-substituted alkenes using complementary strategies
Correction for ‘Rapid access to diverse, trifluoromethyl-substituted alkenes using complementary strategies’ by James P. Phelan et al., Chem. Sci., 2018, 9, 3215–3220.
- 25 May 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 9 (22) , 5119
Open AccessCorrection: Rapid access to diverse, trifluoromethyl-substituted alkenes using complementary strategies
Correction for ‘Rapid access to diverse, trifluoromethyl-substituted alkenes using complementary strategies’ by James P. Phelan et al., Chem. Sci., 2018, 9, 3215–3220.
- Open Access
- 22 February 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 9 (12) , 3215-3220
Rapid access to diverse, trifluoromethyl-substituted alkenes using complementary strategies
Herein describes two complementary methods, a one-step cross-coupling and the functionalization of a ‘masked’ functionality, to access diverse trifluoromethyl alkenes.
- 22 February 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 9 (12) , 3215-3220
Open AccessRapid access to diverse, trifluoromethyl-substituted alkenes using complementary strategies
Herein describes two complementary methods, a one-step cross-coupling and the functionalization of a ‘masked’ functionality, to access diverse trifluoromethyl alkenes.
- Open Access
- 22 February 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 9 (12) , 3186-3191
Engaging sulfinate salts via Ni/photoredox dual catalysis enables facile C sp2 –SO 2 R coupling
This report details the development and implementation of a strategy to construct aryl- and heteroaryl sulfones via Ni/photoredox dual catalysis. Using aryl sulfinate salts, the C–S bond can be forged at room temperature under base-free conditions. An array of aryl- and heteroaryl halides are compatible with this approach. The broad tolerance and mild nature of the described reaction could potentially be employed to prepare sulfones with biological relevance (e.g., in bioconjugation, drug substance synthesis, etc.) as demonstrated in the synthesis of drug-like compounds or their precursors. When paired with existing Ni/photoredox chemistry for Csp3–Csp2 cross-coupling, an array of diverse sulfone scaffolds can be readily assembled from bifunctional electrophiles. A mechanistic manifold consistent with experimental and computational data is presented.
- 22 February 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 9 (12) , 3186-3191
Open AccessEngaging sulfinate salts via Ni/photoredox dual catalysis enables facile C sp2 –SO 2 R coupling
This report details the development and implementation of a strategy to construct aryl- and heteroaryl sulfones via Ni/photoredox dual catalysis. Using aryl sulfinate salts, the C–S bond can be forged at room temperature under base-free conditions. An array of aryl- and heteroaryl halides are compatible with this approach. The broad tolerance and mild nature of the described reaction could potentially be employed to prepare sulfones with biological relevance (e.g., in bioconjugation, drug substance synthesis, etc.) as demonstrated in the synthesis of drug-like compounds or their precursors. When paired with existing Ni/photoredox chemistry for Csp3–Csp2 cross-coupling, an array of diverse sulfone scaffolds can be readily assembled from bifunctional electrophiles. A mechanistic manifold consistent with experimental and computational data is presented.